The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > ORGANIZATION
ORGANIZATION
- Generic Use Rate at 89.0% in January: Payer
June 18, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
- 84% of Pharmacies See More Generic Dispensing after Rollout of New LLP Rule: FPMAJ
June 17, 2025
- FPMAJ Calls for Relaxation of Support Rules for Low-Priced Drugs
June 17, 2025
- FPMAJ Calls for Expanded Range of Selection for Comparator Drugs
June 16, 2025
- PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
June 16, 2025
- JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Hata Comes Back to Helm FIRM after 2 Years
June 10, 2025
- Pharma FTC Revises Food and Drink Rules for Doctors for 1st Time in 10-Plus Years
June 5, 2025
- New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
- New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
- Revamp Drug Price System to Make Room for Wage Hikes: Labor Union
May 29, 2025
- JPMA Revises Definition of Promotion in Code of Practice
May 27, 2025
- FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
- Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
- PhRMA Questions Utility of Proposed Expert Committee for Patent Linkage
May 8, 2025
- Generic Rate in Japan Reaches 89.3% at 2024-End: Payer
May 8, 2025
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…